SHARPE·IQStart free
Menu
TodayResearchEarningsToolsPricingSign in
TMDX reported Third Quarter 2026 results. The stock moved +27.9% on the print.
TMDXearnings

Earnings reactions, page 6

TransMedics Group, Inc. (TMDX) Q3 FY2026 earnings

November 6, 2026 · SharpeIQ Research Desk

Reported results

  • Total revenue of $203.0 million, up 41%, including organic revenue growth of 35% for the third quarter of 2026.
  • Product revenue of $113.4 million, up 29%, and service revenue of $89.6 million, up 60%, including organic service revenue growth of 43% for the third quarter of 2026.
  • Net income of $17.1 million, or $0.46 per diluted share, in the third quarter of 2026.
  • Adjusted net income of $18.9 million, or $0.51 per diluted share, in the third quarter of 2026.
  • Income from operations of $28.1 million, with an operating margin of 13.9% in the third quarter of 2026.
  • Adjusted income from operations of $28.9 million, with an adjusted operating margin of 14.2% in the third quarter of 2026.

Guidance

  • FY 2026 Revenue (excluding PAD Aviation) of $750-$760 million
  • FY 2026 Revenue (including PAD Aviation) of $764-$774 million

Price and volatility reaction

The stock moved +27.9% on the print. No front-expiry chain was on file, so there is no straddle expected move. 30-day ATM implied volatility moved -18.1 vol points across the event (constant-maturity series — not the front-week crush).

MeasureValueBasis
Close before release68.982026-11-05
Close after release88.242026-11-06
Realised move+27.9%close to close
30d ATM IV change-18.1 vol ptsconstant-maturity series, not the front expiry
Price and volatility reaction. Closes either side of the release. No front-expiry chain on file for a straddle expected move. SharpeIQ — listed option chain and price_history

Source

The figures above come from the earnings release the company filed with the SEC on 2026-11-05 (8-K, Item 2.02). Read the original filing on sec.gov.

See this live in SharpeIQ

IV rank, historical IV and the single-ticker tools. The scanner and AI research are paid plans.

Open IV Rank →